Cutler Group’s Haemonetics HAE Stock Holding History

Cutler Group’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-12,600	Closed	-$70K	–	5888
2020 Q4	$70K	Buy	+12,600	New	+$1.36M	﹤0.01%	1767
2017 Q4	–	Sell	-6,000	Closed	-$4K	–	5264
2017 Q3	$4K	Buy	+6,000	New	+$249K	﹤0.01%	4569

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cutler Group's HAE Position: Q4 2019 in Review

Cutler Group sold out of Haemonetics (HAE) in Q4 2019, closing a stake of 9,200 shares — an estimated $1.16M sold.

Cutler Group first reported a position in HAE in Q4 2016 and held it in 2 quarters. The position peaked at $1.16M in Q3 2019. 298 funds tracked by Wall St. Rank hold HAE as of Q4 2019.

Cutler Group reported no remaining Haemonetics position as of Q4 2019 after selling out during the quarter.
Cutler Group sold 9,200 Haemonetics shares in Q4 2019, an estimated $1.16M.
Cutler Group first reported a position in Haemonetics in Q4 2016 and held it in 2 quarters.
Cutler Group's Haemonetics position peaked at $1.16M in Q3 2019.
298 funds tracked by Wall St. Rank held Haemonetics as of Q4 2019.

Based on Cutler Group's 13F filing for Q4 2019, filed 6 Feb 2020.